Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20240364 | 0.89 | GSR (0.61) | GSRCPB2DPP7DPP9DPP8 | |
| SCHEMBL1404247 | 0.89 | GSR (0.61) | GSRCPB2DPP7DPP9DPP8 | |
| SCHEMBL344574 | 0.89 | GSR (0.61) | GSRCPB2DPP7DPP9DPP8 | |
| SCHEMBL680614 | 0.87 | GSR (0.59) | GSRCPB2DPP7DPP9DPP8 | |
| Hydrochloric Acid SCHEMBL3825519 | 0.87 | GSR (0.59) | GSRCPB2DPP7DPP9DPP8 | |
| Hydrochloric Acid SCHEMBL2099474 | 0.87 | GSR (0.59) | GSRCPB2DPP7DPP9DPP8 | |
| SCHEMBL2535190 | 0.86 | GSR (0.50) | GSRCPB2DPP7DPP9DPP8 | |
| SCHEMBL18263222 | 0.86 | GSR (0.55) | GSRCPB2DPP7DPP9DPP8 | |
| SCHEMBL3467172 | 0.86 | GSR (0.50) | GSRCPB2DPP7DPP9DPP8 | |
| SCHEMBL18263219 | 0.86 | GSR (0.50) | GSRCPB2DPP7DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | claimed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | claimed |
| US-11266968-B2 | Mineralizing biosurfactant used for nucleating silica | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-08 | — | — | US | claimed |
| EP-3046870-B1 | SILICA MICRO- AND NANO-CAPSULES AND METHODS FOR MAKING THEM | UNIV QUEENSLAND (AU) | 2021-08-11 | — | — | EP | claimed |
| EP-3630732-A1 | METHOD AND MOLECULES | Medimmune, LLC (US) | 2020-04-08 | — | — | EP | claimed |
| CN-110650947-A | Methods and molecules | 免疫医疗有限责任公司 | 2020-01-03 | — | — | CN | claimed |
| WO-2018218093-A1 | METHOD AND MOLECULES | MEDIMMUNE, LLC (US) | 2018-11-29 | — | — | WO | claimed |
| WO-2003099322-A2 | IL-11 DERIVATIVES AND THERAPEUTIC USES THEREOF | ISIS INNOVATION LIMITED (GB) | 2003-12-04 | — | — | WO | claimed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20220371973-A1 | Method and Molecules | MEDIMMUNE, LLC | 2022-11-24 | — | — | US | disclosed |
| EP-3994115-A1 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3046870-B1 | SILICA MICRO- AND NANO-CAPSULES AND METHODS FOR MAKING THEM | UNIV QUEENSLAND (AU) | 2021-08-11 | — | — | EP | disclosed |
| WO-2007069068-A2 | CELL PENETRATING PEPTIDE CONJUGATES FOR DELIVERING NUCLEIC ACIDS INTO CELLS | DIATOS (FR) | 2007-06-21 | — | — | WO | disclosed |
| EP-1220911-B1 | P-GLYCOPROTEINS AND USES THEREOF | BECTON DICKINSON CO (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060241365-A1 | Implantable Biosensor and Methods of Use Thereof | WILLOW LABORATORIES, INC. | 2006-10-26 | — | — | US | disclosed |
| US-6753177-B1 | USED IN DRUG SCREENING FOR INHIBITORS OF DOG P-GLYCOPROTEIN (PGP) | BECTON DICKINSON AND COMPANY | 2004-06-22 | — | — | US | disclosed |
| EP-1220911-A2 | P-GLYCOPROTEINS AND USES THEREOF | GENTEST CORPORATION (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001023540-A2 | P-GLYCOPROTEINS AND USES THEREOF | GENTEST CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321267-A1 | Method And Molecules | PAICS, EPCAM, SQLE | GSR 1413/4885CPB2 1185/4885DPP7 2428/4885 |
| US-20220371973-A1 | Method and Molecules | VIP, LNPEP, IAPP | GSR 3530/4885CPB2 54/4885DPP7 194/4885 |
| US-11759526-B2 | Method and molecules | PAICS, EPCAM, SQLE | GSR 1413/4885CPB2 1185/4885DPP7 2428/4885 |
| US-11266968-B2 | Mineralizing biosurfactant used for nucleating silica | SGMS2, PHOSPHO1, SOST | GSR 1900/4885CPB2 2465/4885DPP7 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.